Search results
Merck's KEYTRUDA shows survival benefit in gastric cancer trial By Investing.com
Investing.com· 1 day agoMerck & Co., Inc., a leading pharmaceutical company, announced positive results from the Phase 3...
Project Optimus: helping or hindering cancer drug development?
Clinical Trials Arena via Yahoo Finance· 14 hours ago“In small companies, it is always difficult because resources are constrained and the people...
Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoGlobalData is the parent company of Pharmaceutical Technology. Pfizer is also seeking European...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 1 day agoProgression-free survival is how long patients live before their cancer worsens. The company added...
Stock market today: gloomy start to May ahead of Fed decision
Newsweek· 1 day agoU.S. futures were down Wednesday morning ahead of a decision by the Federal Reserve on interest...
FDA grants full approval to cervical cancer drug TIVDAK By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of...
Are Ultra-Processed Foods Really all that Unhealthy?
Scientific American· 6 days agoThe problem, according to this increasingly popular argument, is that we’re eating lots of ultra-processed food or UPF. Traditionally, people used...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 3 days agoCOPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental ...
AbbVie Reports First-Quarter 2024 Financial Results
The Hannibal Courier-Post· 6 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - G1...
Benzinga· 1 day ago- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results